Self-Amplifying RNA Vaccines Patent Landscape Analysis 2024: By Application: Oncology, SARS-Cov-2, Hepatitis, HIV, Influenza and Veterinary; By Carrier: VRP, LNP, Liposome, CNE, Polymer; Key Player Profiles

Self-Amplifying RNA Vaccines Market Size

Self-amplifying RNA vaccine technology offers both faster production timelines and greater disease-neutralising antibodies. Data suggests that by the end of 2023, 12  DNA-based and mRNA-based oncology vaccines were either approved or in the pre-registration stage. In recent years, developments in the industry have highlighted the potential of saRNA in vaccines and therapeutics. There has been a significant increase in number of patent applications associated with saRNA vaccines, driven by technological advancements.

Patent Landscape Report Coverage

The self-amplifying RNA vaccines patent landscape report provides a comprehensive and in-depth analysis of the patents in this industry. The key sections captured in the report for self-amplifying RNA vaccines include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within self-amplifying RNA vaccine technologies.

A 2023 trial utilised TriLink’s patented technology CleanCap AU analog to synthesize 26 unique self-amplifying RNA variants. Each variant substitutes a nucleoside with a modified counterpart. This has led to improvements in cellular expression. Therefore, such technical innovations are impacting the patent landscape significantly.

    
Self-Amplifying RNA Vaccines Patent Market Outlook

• The significant increase in investment for securing patents for vaccine technology including saRNA constructs, formulations, and carrier systems is expected to increase the patent filing in coming years.

• Key pharmaceutical companies, academic institutions, and biotech firms are actively filing patents to protect their innovations within saRNA aspects. The competitive dynamics are intensifying as other players are entering the field.

• Several major companies and institutions are adopting strategic initiatives to build strong patent portfolios. The strategy includes filing patent applications early in the process of development to secure priority rights, engaging in patent licensing, and conducting comprehensive patent searches to avoid any infringement.

What are Self-Amplifying RNA Vaccines?

Self-amplifying RNA (saRNA) vaccines utilize a self-replicating RNA platform to produce immune responses in the body. The RNA vaccines aim to stimulate the immune system to defend against specific pathogens. However, RNA vaccines use genetic material, specifically, messenger RNA, instead of using inactivated viruses and instruct cells to produce a protein. Self-amplifying RNA vaccines are a specialized kind of RNA vaccine. They allow the RNA to replicate by itself within the host cells. This self-amplification process results in a strong immune response and higher levels of protein production.

saRNA vaccine produces enhanced immunogenicity, lower doses required due to its self-amplifying nature and rapid production. This continues to drive the development of saRNA vaccine technology, resulting in higher patent filings.

Self-Amplifying RNA Vaccines Industry Growth Drivers

Advancements in RNA Delivery Systems is Expected to Boost Patent Applications

The advancement in RNA delivery systems is crucial for the efficacy of self-amplifying RNA vaccines. The most used platform to encapsulate and protect RNA molecules is lipid nanoparticles. It facilitates the delivery into cells and enhances stability. The improvements in lipid nanoparticle design, such as surface charge, optimizing particle size, and lipid composition, have enhanced the efficiency of vaccine delivery.

As per an article published by NCBI, self-amplifying RNA requires a carrier to promote cellular uptake. The available delivery platforms are lipid nanoparticles, cationic nanoemulsions and polyplexes. Lipid nanoparticles are the most clinically advanced carrier with the recent FDA approval of COVID-19-based modified mRNA vaccines. The advent of such new tools and enhanced products in the market influences the patent landscape as researchers and companies take effective measures to secure patents and protect their innovations.

RNA Engineering and Optimization Advancements to Propel Self-Amplifying RNA Vaccines Patent Industry Growth

The advancement in RNA engineering has developed the design of saRNA molecules which are efficient in amplification, more stable, and capable of inducing robust immune responses. The techniques such as sequence modifications for enhanced translation, and codon optimization have improved the safety and efficacy of saRNA vaccines. In 2023, 1300+ patents were granted for saRNA vaccines signifying their efficacy and safety in therapeutic applications.

Self-Amplifying RNA Vaccines Patent Segmentation

The report will cover the following sections in detail:

Breakup by Application

• Oncology,

• SARS-Cov-2

• Hepatitis

• HIV

• Influenza

• Veterinary

Breakup by Carrier

• VRP

• LNP

• Liposome

• CNE

• Polymer

Self-Amplifying RNA Vaccines Patent Segmentation Analysis

The breakup based on carrier includes VRP, LNP, liposome, CNE and polymer. Self-amplifying RNA vaccine investigations have been conducted with the chosen patent families labelled based on the platforms to which they pertain. For instance, AAHI, a biotech research institute, invented a novel self-amplifying RNA vaccine platform and a unique RNA carrier called nanostructured lipid carrier (NLC). The nanostructured lipid carrier (NLC) contains oil at its core with characteristics to boost the immune response to the target disease.

The detailed technological data will be provided for all specified segments classified in this report.

Self-Amplifying RNA Vaccines Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for self-amplifying RNA vaccine patents, having around 48,000 patents. The presence of a well-established healthcare infrastructure, a robust legal framework, and prominent research institutions engaged in innovations contributes to the patent landscape significantly.

Patent Profile of Key Companies

Among the players with self-amplifying RNA vaccine patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Gentech Inc.

Genentech is a leading global biotechnology company engaged in innovations in oncology, and other therapeutic areas. The company is developing RNA-based technologies - self-amplifying RNA vaccines.

Novartis AG

Novartis is a global pharmaceutical company, engaged in investigating the self-amplifying RNA vaccines’ potential. Novartis has filed numerous patents to protect its IP within self-amplifying RNA vaccine technologies.

Other companies include Hu man Genome Sciences, Inc., Immatics Biotechnologies GmbH, Broad Institute Inc., Bristol Myers Squibb Co., Millenium Pharm Inc., University of Texas, University of California, and Harvard College, among others.

Reasons to Purchase this Report

The self-amplifying RNA vaccines patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by - 

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators and also makes it understandable which companies have important patents in this field of self-amplifying RNA vaccines.

• Innovation Insights: The patent analysis reveals innovations and technologies in the self-amplifying RNA vaccines industry.

• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry.

• Risk Assessment: In technology-intensive fields such as self-amplifying RNA vaccines, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

Key Questions Answered in the Self-Amplifying RNA Vaccines Patent Landscape Report

• Who are the key players in the self-amplifying RNA vaccine patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in self-amplifying RNA vaccine patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in the self-amplifying RNA vaccines industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in self-amplifying RNA vaccines?
• What are the challenges and opportunities in the self-amplifying RNA vaccine patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in self-amplifying RNA vaccines?

RELATED REPORTS

Global mRNA Vaccines and Therapeutics Market

Global Travel Vaccines Market

Global Antisense and RNAi Therapeutics Market

Global Recombinant DNA Technology Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.